Top 10 vaccine manufacturers in the world

Malini T
·7 min read
COVID-19 vaccines in focus
Coronavirus vaccines on the production line: World's largest vaccine companies

Until the coronavirus pandemic hit humanity hard, information about pharmaceutical companies and vaccine producers was not sought often. But now, more than ever, their credibility makes all the difference to the human race. 

Here's a look at the 10 biggest vaccine makers in the world as of 2021:

Curevac

CureVac N.V. is a German biopharmaceutical company, legally domiciled in the Netherlands and headquartered in Tübingen, Germany, that develops therapies based on messenger RNA (mRNA). The company's focus is on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. In January 2021, CureVac announced a clinical development collaboration for its COVID-19 vaccine, named CVnCoV (active ingredient zorecimeran), with the multinational pharmaceutical company, Bayer. As of December 2020, CVnCoV was in a Phase III clinical trial of 36,500.

Total market cap: $19.153 billion

Total revenue: $19.49 million

Total assets of the company in 2019: $64.18 million

Number of employees: less than 500

Biontech

BioNTech SE (short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualised cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.

In 2020, BioNTech, in conjunction with Pfizer, developed the RNA vaccine BNT162b2 for preventing COVID-19 infections, which offers a 95% efficacy. On 2 December 2020, temporary HMR authorisation was granted by the United Kingdom government for BNT162b2 vaccinations within the UK. It was the first mRNA vaccine ever authorized. Some days later the vaccine also got an emergency approval in the United States, Canada, and Switzerland. On 21 December 2020, the European Commission approved BioNTech/Pfizer's coronavirus vaccine in accordance with the positive recommendation of the European Medicines Agency (EMA)

Total market cap: $29.26 billion

Total revenue: $131.43 million

Total assets of the company in 2019: $965.39 million

Number of employees: 1,323

Chongqing Zhifei Biological Products

Chongqing Zhifei Biological Products Co., Ltd. is a China-based organisation primarily occupied with the exploration, improvement, creation, sale, and distribution of Vaccine items. The Company's main items include bacterial vaccines, biological products for the prevision and treatment of tuberculosis, and other biological products. In 2020 when the COVID-19 pandemic just broke out, the Company took initiative to donate RMB10 million to Hubei Province for pandemic control.

Total market cap: $37.52 billion

Total revenue of the company: $1.657 billion

Total assets of the company in 2019: $1.278 billion

Number of employees: 2,972

Moderna

Moderna is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It focuses on drug discovery, drug development, and vaccine technologies based on messenger RNA (mRNA). Moderna's technology platform inserts synthetic nucleoside-modified mRNA (modRNA) into human cells using a coating of lipid nanoparticles. This mRNA then reprograms the cells to prompt immune responses. It is a novel technique, abandoned by other manufacturers due to concerns about the toxicity of lipid nanoparticles at high or frequent doses.

In November 2020, it was announced that the Moderna COVID-19 vaccine candidate (codenamed mRNA-1273), had shown preliminary evidence of 94% efficacy in preventing COVID-19 disease in a Phase III trial, with only minor flu-like side effects. This led to its submission for emergency use authorisation (EUA) as a COVID-19 vaccine in Europe, the United States, and Canada. On December 18, 2020, mRNA-1273 was issued an EUA in the United States. On December 23, 2020, it was authorised for use in Canada. On January 6, 2021, it was authorised for use in the European Union. On January 8, 2021, mRNA-1273 was authorised for use in the United Kingdom. On March 15, 2021, mRNA-1283 was started for the phase I clinical trial.

Total market cap: $44.616 billion

Total revenue: $94.47 million

Total assets of the company in 2019: $1.924 billion

Number of employees: 1000+

Glaxo Smith Kline

GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company headquartered in London, England.[3] Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world's sixth largest pharmaceutical company according to Forbes as of 2019, after Pfizer, Novartis, Roche, Sanofi, and Merck & Co. In July 2020, the UK government signed up for 60 million doses of a COVID-19 vaccine developed by GSK and Sanofi. It uses a recombinant protein-based technology from Sanofi and GSK's pandemic technology. The companies claimed to be able to produce one billion doses, subject to successful trials and regulatory approval, during the first half of 2021. The company also agreed to a $2.1 billion deal with the United States to produce 100 million doses of the vaccine.

Total market cap: $96.115 billion

Total revenue of the company: $40.832 billion

Total assets of the company in 2019: $96.403 billion

Number of employees: 99,437

Sanofi

Sanofi S.A. is a French multinational pharmaceutical country settled in Paris, France, as of 2013 the world’s fifth-biggest company by sales. In February, Sanofi began working with BARDA to utilize its recombinant DNA stage to test a preclinical immunization candidate for COVID-19. Sanofi together with GSK signed a deal with US government's Operation Warp Speed to provide 100 million doses COVID-19 vaccine for up to 2.1 billion USD, if the vaccine is approved. Sanofi plans to start Phase 1 clinical testing only in September and expects emergency use approval in first half 2021.

Total market cap: $121.45

Total revenue of the company: $43.70 billion

Total assets of the company in 2019: $136.377 billion

Number of employees: 100,409

AstraZeneca

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company. Cambridge Biomedical Campus in Cambridge, England.It has a portfolio of products for major diseases in areas including oncology , cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It is perhaps best known for its involvement in developing the Oxford-Astrazeneca COVID-19 vaccine.

Total market cap:$133.055 billion

Total revenue of the company: $23.565 billion

Total assets of the company in 2019: $61.377 billion

Number of employees: 70,600

Merck

Merck and Co., Inc., d.b.a. Merck Sharp and Dohme (MSD) outside the United States and Canada, is an American worldwide pharmaceutical company based in New Jersey. Medically significant antibodies created at Merck incorporate the first-ever mumps vaccine, the primary rubella vaccine, and the main trivalent measles, mumps, rubella (MMR vaccine).

Total market cap: $210.068 billion

Total revenue of the company: $46.840 billion

Total assets of the company in 2019: 84.397 billion

Number of employees: 71000

Pfizer

Pfizer Inc. is an American worldwide pharmaceutical enterprise. It is positioned 64 on the 2020 Fortune 500 rundown of the biggest United States Corporation on basis of total revenue. Headquartered in Manhattan, Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. 

In May 2020, Pfizer began testing four different COVID-19 vaccine variations. It planned to expand human trials to thousands of test patients by September 2020. The pharma company injected doses of the potential vaccine BNT162b2, which was developed by the German biotechnology company BioNTech, into the first human participants in the U.S. in early May. Based on the results, Pfizer said they "will be able to deliver millions of doses in the October time frame" and expects to produce hundreds of millions of doses in 2021.

Total market cap: $206.383 billion

Total revenue of the company: $51.750 billion

Total assets of the company in 2019: $167.489 billion

Number of employees: 88,300

Johnson & Johnson

Johnson and Johnson (J&J) is an American global corporation established in 1886 that creates medical devices, consumer goods, and pharmaceuticals. It is viewed as a central participant in the COVID-19 vaccine race. 

Total market cap: $421.312 billion

Total revenue of the company in 2019: $82.059 billion

Total assets of the company in 2019: $157.728 billion

Number of employees: 132,200

Also read:

This content is not available due to your privacy preferences.
Update your settings here to see it.

Ref source: https://meticulousblog.org/top-10-companies-in-vaccines-market/

https://www.insidermonkey.com/

Wikipedia